All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Epstein-Barr virus (EBV) is the only human-adapted member of the *Lymphocryptovirus* genus, belonging to a lineage of Old World primate gamma-1 herpesviruses that was transferred to a hominid ancestor approximately twelve million years ago, and which is now responsible for near-universal and lifelong human infection \[[@pone.0147567.ref001],[@pone.0147567.ref002]\]. Viral transmission is generally via saliva, with evidence that age of infection is associated with cultural and socioeconomic factors \[[@pone.0147567.ref003]\]. Uniquely, chronic infection is established within 'immortalised' B-lymphocytes that are transformed by an array of viral proteins that functionally mimic host proteins to create long-lived memory cells \[[@pone.0147567.ref004],[@pone.0147567.ref005]\]. Viral persistence is then promoted through mechanisms that reduce antigen presentation to the adaptive immune system \[[@pone.0147567.ref006]\], including the involvement of latency programs that limit viral protein expression to a minimal subset critical for replication; most notably Epstein-Barr Nuclear Antigen-1 (EBNA-1), which maintains host chromosomal attachment of viral episomal DNA thus linking viral and cellular replication cycles \[[@pone.0147567.ref007]\].

These mechanisms of viral persistence would predict limited viral sequence diversity, in keeping with the relatively slow evolutionary rate of EBV and other gamma-1 herpesviruses \[[@pone.0147567.ref002]\] and evidence of geographically-defined viral subtypes \[[@pone.0147567.ref008]\]. Nevertheless, evidence of diversifying selection involving latency genes including EBNA-1 has been identified \[[@pone.0147567.ref009]\], including preferential variation within human leukocyte antigen (HLA) binding sites (viral epitopes) suggesting that antigen presentation can promote HLA-specific viral escape mutations \[[@pone.0147567.ref010],[@pone.0147567.ref011]\]. Thus, EBNA-1 is not immunologically 'silent' as once thought \[[@pone.0147567.ref012]\] but is an antigenic target for both CD4 and CD8 T-cell responses \[[@pone.0147567.ref012]--[@pone.0147567.ref014]\] as well as antibodies \[[@pone.0147567.ref015]\], in keeping with finely tuned immune surveillance mechanisms that generally maintain persistent but stable cycles of EBV infection involving both epithelial and B-lymphocyte compartments \[[@pone.0147567.ref005]\]. Within this paradigm, mechanisms of viral antigen display \[[@pone.0147567.ref013],[@pone.0147567.ref014]\] and the general hierarchy of EBV-specific immune responses including regulatory as well as effector T cell responses are being examined \[[@pone.0147567.ref014],[@pone.0147567.ref016]--[@pone.0147567.ref018]\]. These have particular relevance to the therapeutic application of EBV-specific T-cell adoptive immunotherapy against EBV-related malignancies including Burkitt's and Hodgkin's lymphoma and nasopharyngeal carcinoma \[[@pone.0147567.ref019]\], now supported by positive findings in clinical trials \[[@pone.0147567.ref020],[@pone.0147567.ref021]\]. This strategy is underpinned by knowledge of EBV sequence diversity in tissue samples \[[@pone.0147567.ref009],[@pone.0147567.ref022],[@pone.0147567.ref023]\] and its utilisation to predict viral epitope targets \[[@pone.0147567.ref024]\].

Our own investigations have focused on multiple sclerosis, an inflammatory demyelinating disease of the central nervous system that often leads to neurodegeneration and long-term disability despite current treatment strategies \[[@pone.0147567.ref025]\]. While a comprehensive explanation of multiple sclerosis pathogenesis remains incomplete, it is clear that the major component of genetic risk is associated with the HLA-DR locus \[[@pone.0147567.ref026]--[@pone.0147567.ref029]\], thus implicating HLA-restricted antigen binding and presentation \[[@pone.0147567.ref030]\], as well as genetic determinants that predominantly relate to T-cell activation \[[@pone.0147567.ref029]\]. Several lines of evidence link Epstein-Barr virus-specific immunity to multiple sclerosis risk. Both serological \[[@pone.0147567.ref027],[@pone.0147567.ref031],[@pone.0147567.ref032]\] and CD4 T cell responses \[[@pone.0147567.ref033]\] directed against EBNA-1 have been associated with multiple sclerosis, with further evidence that EBNA-1-specific antibodies differentiate disease-discordant identical twins \[[@pone.0147567.ref034]\]. Several groups have demonstrated higher EBV seroprevalence in MS patients compared to controls and it has further been demonstrated that EBV infection late in life, in particular if manifested as infectious mononucleosis, increases a person's MS risk \[[@pone.0147567.ref027], [@pone.0147567.ref035], [@pone.0147567.ref036]\]. A recent study has also explored the use of Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis, with promising preliminary results \[[@pone.0147567.ref037]\]. Further observations include that cerebrospinal fluid oligoclonal bands that are a hallmark of MS specifically can target EBNA-1 \[[@pone.0147567.ref038]\] and one group has additionally identified the presence of EBV-infected B cells within white matter MS lesions at all disease stages \[[@pone.0147567.ref039]\], although this result has not been replicated in other studies \[[@pone.0147567.ref040]\].

In this study, we have utilised DNA obtained from buffy coat samples of patients with multiple sclerosis to analyse EBNA-1 sequence variation using both Sanger and FLX 'next-generation' sequencing technologies, without any requirement for primary culture techniques or the creation of cell lines through *ex vivo* EBV transformation. We have then sought to identify potential HLA-DRB1\*1501-restricted viral epitopes within the EBNA-1 protein sequence using standard HLA binding algorithms \[[@pone.0147567.ref041]\], and investigated potential homology with similarly HLA-restricted antigens in a dataset of human central nervous system proteins \[[@pone.0147567.ref042]\]. The results of this study, which follow from our previous investigations of the contributions made by HLA alleles and Epstein-Barr virus immunity to multiple sclerosis risk \[[@pone.0147567.ref027],[@pone.0147567.ref028]\], highlight the divergence of autologous 'wild-type' EBNA-1 sequences from those of laboratory strains commonly used for experimental purposes, and suggest possible avenues of investigation that acknowledge both host and viral genetic diversity in higher-resolution analyses of the role of host-pathogenic interactions in autoimmunity \[[@pone.0147567.ref030],[@pone.0147567.ref043],[@pone.0147567.ref044]\].

Materials and Methods {#sec006}
=====================

Research participants {#sec007}
---------------------

A total of 79 study participants in the Perth Demyelinating Disease Database (PDDD) were included in the study. The study protocol was approved by the Sir Charles Gairdner Hospital Human Research Ethics Committee, and written informed consent was obtained from all participants.

DNA extraction {#sec008}
--------------

DNA was isolated from buffy coats (stored at -80°C) using an automated robotic setup using Genfind according to the manufacturer's instructions. Briefly, 100ul of buffy coat were lysed and Proteinase K added to rupture cell membranes and digest protein. DNA was then immobilized on magnetic particles by the addition of a magnetic bead binding reagent. DNA was separated from contaminants using a magnetic field and washing steps. DNA was eluted in 125μl from the magnetic particles. A minority of samples were manually extracted using Qiagen with the provided protocol. 200μl of buffy coat were lysed and Proteinase K added to remove protein and other contaminants. DNA was absorbed on to the silica-gel membrane during centrifugation of columns and then washed twice to ensure complete removal of any residual contaminants. Finally, samples are recovered from the membrane using 200μL elution buffer. Concentration of all eluted samples was determined using Nanodrop and 1 μl of each sample was loaded on a 1% agarose gel to test for presence and integrity of DNA. All samples were stored at 4°C until further use.

HLA typing {#sec009}
----------

PCR and sequencing based HLA genotyping of the MS cohort resolved to at least the 4-digit level was performed as previously described using heterozygous ambiguity resolving primers where applicable \[[@pone.0147567.ref027],[@pone.0147567.ref028]\].

EBV amplification {#sec010}
-----------------

The N- and C-terminal ends excluding the glycine-alanine rich regions of the EBNA-1 gene were amplified using semi-nested PCRs and fully automated setup utilising Biomek FX robots. EBV reference strain B95-8 was extracted from a B95-8 transformed cell line and was diluted and used as a control in each EBV PCR. All PCR reactions were performed using Roche High Fidelity Taq in 25μl reactions with forward and reverse primers at a concentration of 25pmol/μl. All primers used for amplification have been previously published and named according to the position in the reference strain B95-8 \[[@pone.0147567.ref011],[@pone.0147567.ref045],[@pone.0147567.ref046]\], as summarised below:

1.  107754F: TCCGGGCTGCGAGTAATTGG

2.  107881F: GTCTGCACTCCCTGTATTCA

3.  109111F: TCATCATCATCCGGGTCTCCACCGC

4.  108160R: GGACACCATCTCTATGTCTTGGCC

5.  109135R: GCGGTGGAGACCCGGATGATGATGA

6.  109459R: CCCAAGTTCCTTCGTCGGTAGTCC

7.  109759R: CTCCATCGTCAAAGCTGCA

8.  109869R: CTGCCCTTCCTCACCCTCAT

9.  109970R: CAACAGCACGCATGATGTCT

For amplification of the N-terminal end the first round primer pair 107754F-109135R (PCR1) resulting in a 1381 base pair fragment (bp) was used. Detailed information about size and location of EBNA-1 PCRs with reference to the EBV strain B95-8 can be found in [S1 Fig](#pone.0147567.s001){ref-type="supplementary-material"}. Second round amplification was then performed using either 107881F-109135R (PCR2) or 107754F-108160R (PCR3), resulting in 1254bp or 406bp fragments respectively. C-terminal EBNA-1 PCR was performed as described previously \[[@pone.0147567.ref027]\]. Briefly, first round amplification with the primer pair EBV109111F-EBV109970R (PCR 4) resulted in an 859bp fragment. A semi-nested PCR was followed using the primer combination 109111F-109869R (PCR5) resulting in a final 758 base pair product. Alternatively, shorter semi-nested PCRs were performed using the primer combinations 109111F-109759R (PCR6, 648bp) and 109111F-109459R (PCR7, 348bp) respectively. In some cases PCRs with alternative primers have been performed. For an overview of primer pairs used in each PCR, nucleotide coordinates of primers within the B95-8 reference strain as well as primer melting temperatures, elongation times and product sizessee [S1 Table](#pone.0147567.s002){ref-type="supplementary-material"}. Successful PCR samples were purified using magnetic particles with AMPure (Beckman Coulter) on Biomek FX robots and stored at 4°C until further use.

Sanger sequencing and analysis {#sec011}
------------------------------

Samples were directly sequenced on an automated 96 capillary ABI 373 DNA Sequencer, followed by purification of sequencing products with magnetic particles using CleanSEQ (Beckman Coulter) on Biomek FX robots. Analysis of electropherograms was performed using the ASSIGN V4.0.1.36 software (Conexio Genomics). Threshold for mixture detection in Sanger sequencing has been established to be \~30%. For construction of the Phylogenetic tree, 53 MS sequences and reference strains B95-8, AG876, GD1 and HKNPC1 covering the majority of nucleotide positions B95-8: 109135--109815 (EBNA-1: 1186--1866) were included. Genetic distance was visualized using the Neighbour-joining method based on the p-distance model with pairwise deletion within the PHYLIP (Phylogeny Inference Package) version 3.695 \[[@pone.0147567.ref047]\].

454 FLX sequencing {#sec012}
------------------

For the 454 FLX sequencing strategy, 24 samples were pooled in a single FLX lane. 20 MS samples were selected based on successful Sanger sequencing for three epitopes of interest (EBNA-1 aa PPP: 401--416, AEG: 482--496 and MVF: 563--577). Three additional MS samples were included that displayed a band of correct size on a 1% agarose gel but were not successfully sequenced by Sanger methods. The B95-8 strain of EBV was used as a control in each EBV PCR and was also selected as a control for FLX sequencing.

First round C-terminal EBV PCRs products with the primer combination EBV109111F-EBV109970R (PCR4) were used as templates to generate shorter second round PCRs for the selected deep sequencing samples. For PCR length and location please refer to [S1 Fig](#pone.0147567.s001){ref-type="supplementary-material"}. This nested PCR was performed with molecular barcoded primers. These tags consisted of eleven nucleotides unique extension to the 5' end of the second round primers EBV109111F and EBV109869R (PCR5b) resulting in 780bp amplicons. This method facilitates sample multiplexing while also increasing the ability to accurately assign reads back to the sample. Resulting PCR amplicons were pooled at equimolar ratios (3x10^11^ copies each) to achieve similar number of reads. Standard Library was constructed using 454 Roche Titanium Chemistry protocol. The denatured DNA library was immobilized onto beads and emulsified with the amplification reagents in a water-in-oil mixture and clonally amplified (emPCR). Following emPCR, the capture beads with bound DNA were enriched according to the 454FLX titanium manual and used for pyrosequencing on one lane of an eight lane 454 FLX sequencing run according to the 454 sequencing manual.

The reads obtained from the sequencing were separated according to the unique tags and linked back to the original samples, using the Next*GENe* software package from SoftGenetics, Inc (State College, PA, USA). Further analysis was performed with inhouse software.

FLX data analysis {#sec013}
-----------------

The Next*GENe* software package version 2.3.0 (SoftGenetics, Inc, USA) was used to create a consensus sequence present at \>45% for each sample based on the B95-8 EBV reference strain (GenBank accession number: V01555.2). For each sample, all reads were aligned to the consensus using a pairwise alignment. The pairwise alignments were combined into a multiple alignment by matching the reference positions for all aligned pairs. The aligned files were used to detect homopolymers, which are known to occur in FLX sequencing as artefacts. During analysis, all homopolymers not present in the respective consensus sequence have been excluded. Minorities present at \<1% were not taken into consideration and insertion deletions were also excluded except for a strain specific in-frame insertion of three amino acids (glycine (GGA), aspartic acid (GAT), aspartic acid (GAC)) at position 2367 of EBNA-1 position (109818/109819 of reference strain B95-8) in several samples, which has been described previously \[[@pone.0147567.ref011]\]. All mutations detected were additionally manually analysed in the raw FLX data file of each sample to exclude any contribution of homopolymer errors. A nucleotide change was considered a real mutation if the mutation could not have been caused by a nucleotide insertion/deletion before or after the mutation. Additionally, mutations were only taken into consideration if they were present in at least three sequences, independent of the total number of individual reads per sample. Mutations within three nucleotides from the beginning or end of a read were excluded. Furthermore, unresolved nucleotide mixtures within reads were few, but indicated low signal quality in this position and were not taken into consideration.

Epitope predictions {#sec014}
-------------------

HLA binding algorithms (NetMHCII, NetMHCIIpan) were utilized to identify potential HLA-DRB1\*1501 class II HLA epitopes within the EBNA-1 Sanger derived sequences. Additionally, predictions were performed for two known HLA-DRB1\*1501 class II EBNA-1 epitopes (denoted AEG and MVF) using all FLX consensus and Sanger sequences generated. All predicted 15mer peptides which resulted in HLA-DRB1\*1501 strong (\<50 nM) and weak binders (50--500 nM) were selected and tested for potential cross-reactivity on a dataset of CNS proteins enriched for axoglial proteins (human protein reference database ([HPRD.org](http://HPRD.org)) and \[[@pone.0147567.ref042]\], as well as a selection of brain proteins derived from NCBI ([S2 Table](#pone.0147567.s003){ref-type="supplementary-material"}). Amongst these potential cross-reactive epitopes, a subset of epitopes sharing the majority of peptide amino acid residues within the epitope core HLA-binding sequence of nine amino acids, were identified.

Statistical analysis {#sec015}
--------------------

We assessed whether EBNA-1 nucleotide polymorphism at each position was significantly associated with MS risk alleles by grouping alleles according to previous genetic analysis by our group \[[@pone.0147567.ref027]\]. Samples were categorized as carrying high MS risk, low MS risk or neutral risk alleles, respectively, if they carried at least one risk allele (HLA-DR1\*08, \*15, \*16); at least one protective allele (HLA-DR1\*04, \*07, \*09) and no risk allele; or two neutral risk alleles. Tables of nucleotide frequencies by risk groups were created at each nucleotide position and associations assessed by Fisher exact tests. We assessed clustering based on all 62 C-terminal Sanger sequences using the "partitioning around medoids" (PAM) method \[[@pone.0147567.ref048]\]. All nucleotide positions demonstrating some nucleotide variation were included and clusters displayed via a plot of the first two principal components \[[@pone.0147567.ref048]\]. Associations of HLA risk groups with viral clusters found in the cluster analysis were also assessed using Fisher exact tests. Analyses were carried out using TIBCO Spotfire S+ 8.2 (Somerville, MA).

Results {#sec016}
=======

Epstein Barr Nuclear Antigen-1 (EBNA-1) was successfully amplified for bulk (Sanger) sequencing in 76 MS samples from DNA extracted buffy coats without any requirement for primary culture to enrich for EBV episomes. All samples were obtained from participants in the Perth Demyelinating Disease Database (PDDD) with confirmed MS, reflecting a wide range of age and disease severity ([Fig 1](#pone.0147567.g001){ref-type="fig"}). Females were more prevalent (73%) than males (27%) in the study population, with a slightly higher age (median: 53) compared to males (median: 49). Within this dataset, 62 samples were successfully sequenced across the EBNA-1 C-terminal region, which is known to contain the majority of MHC Class II-restricted T-cell epitopes \[[@pone.0147567.ref049]--[@pone.0147567.ref051]\], and a subset of 37 samples was sequenced in the N-terminal EBNA-1 region additionally. Sequences for both the N- and C-terminal end were obtained from 23 samples.

![Age and gender distribution of patients recruited from the Perth Demyelinating Disease Database.](pone.0147567.g001){#pone.0147567.g001}

Wild-type EBNA-1 sequence variation {#sec017}
-----------------------------------

The C-terminal region of EBNA-1 demonstrated sequence variation within four major clusters with additional minor variation ([Fig 2](#pone.0147567.g002){ref-type="fig"}). In keeping with previous analyses of wild-type EBNA-1 sequences \[[@pone.0147567.ref009],[@pone.0147567.ref011]\], wild-type sequences showed strong similarity to the EBV reference strain B95-8 in only a minority of cases (9/53, 16.9%) and none clustered with the type 2 AG876 strain. No nucleotide mixtures were identified by Sanger sequencing methods that would indicate the presence of multiple EBNA-1 populations, either as a result of mutation or superinfection with multiple strains. N-terminal sequence analysis showed high conservation and identified only three different variants: 19 samples demonstrated 100% sequence similarity with the N terminal sequence of the EBV reference strain B95-8, while 12 sequences matched the previously identified type 2 EBV strain AG876 which differs to B95-8 in the positions: Q16E, E18G, D24E, S27G and A85T \[[@pone.0147567.ref052]\]. Three of these positions (Q16E, E18G, S27G) have previously been described to occur in combination (44). The third variant occurred in seven samples and aligned well with AG876 but contained two mismatches to it: EBNA-1 amino acid positions: V70A), (Q74P.

![Phylogenetic tree of C-terminal EBNA-1 Sanger sequences including the reference strains B95-8, AG876, GD1 and HKNPC1.\
Phylogenetic tree covering nucleotide positions B95-8: 109135--109815; EBNA-1: 1186--1866; blue triangles: EBV reference strains; red dots: MS cases (n = 53).](pone.0147567.g002){#pone.0147567.g002}

Association of HLA and viral sequence variation {#sec018}
-----------------------------------------------

Association analysis of MS risk group with EBNA-1 sequence variation revealed nine positions at which individuals in the high risk group had nucleotide frequencies significantly differing from the other risk groups with p\<0.05 --namely positions 1428 (P476), 1460 (A487), 1475, (S492), 1498 (D499), 1690 (M563), 1722 (V574), 1754 (T585), 1782 (R594) and 1785 (V595). Cluster analysis based on the C-terminal Sanger sequences described in Methods revealed two distinct populations ([Fig 3](#pone.0147567.g003){ref-type="fig"}), a main cluster (A) of 47 cases and a smaller cluster (B) of 15 cases. Across the nine positions with significant HLA association there were 373 consensus nucleotides and seven non-consensus among the 47 cases in cluster A and just 10 consensus nucleotides and 109 non-consensus in cluster B. Hence at these nine positions the two clusters were almost mutually exclusive.

![Principal Component plot (Component 1 vs Component 2) for cluster analysis based on the C-terminal EBNA-1 Sanger sequences revealed two distinct populations of 47 (A) and 15 (B) cases.](pone.0147567.g003){#pone.0147567.g003}

When assessed for HLA MS risk group, cluster A contained 5, 9 and 33 individuals classified as MS risk neutral, protective and high, respectively, compared with the smaller cluster (B) which contained 4, 6 and 5 individuals with neutral, protective and high MS risk. The high MS risk group was thus significantly over-represented in the large cluster (p = 0.016).

454 deep sequencing {#sec019}
-------------------

Additional sequencing of the C-terminal EBNA-1 fragment (EBNA-1 nucleotide positions 1160--1906) was then undertaken utilising FLX technology for 23 samples and a B95-8 control. Among these, 14 samples and the B95-8 control had coverage of all positions between 80--1632 reads, while 10 samples had very low coverage of reads per position (average reads \<15) and were not included in subsequent sequence minority analysis. As shown in [Table 1](#pone.0147567.t001){ref-type="table"}, low-level EBNA-1 sequence variation could be detected although only two samples (samples 1 and 5) showed the presence of minor sequence variants at a level of ≥10%. Mixtures occurred at nucleotide positions 1190 (R397) and 1588 (P529) in sample 1 and at 14 different positions in sample 5: 1286 (V429), 1420 (G473), 1421 (S474), 1428 (P476), 1460 (A487), 1475 (S492), 1498 (D499), 1561 (L520), 1572 (T524), 1660 (P553), 1690 (M563), 1722 (V574), 1754 (T585), 1782 (R594) and 1785 (V595). Silent mutations occurred at amino acid positions G473, D499, L520, P529 and P553, whereas the other mutations lead to a mixture of wild type and variant amino acids: R397R/G, V429V/M, S474S/T, P476P/Q, A487A/T, S492S/C, T524/TI, M563M/I, V574V/G, T585T/P, R594R/K and V595V/A. Lowering this threshold to 5% revealed minority variants in 3.6% positions (27/749 nucleotides sequenced); increasing to 5.0% at a 2% cut-off (37/749 nucleotides) and 8.3% at a 1% cut-off (62/749 nucleotides). As noted in [Table 1](#pone.0147567.t001){ref-type="table"}, most of the mutations that defined minority variants were unique to individual samples (42 individual positions) ([Table 1](#pone.0147567.t001){ref-type="table"}).

10.1371/journal.pone.0147567.t001

###### EBNA-1 quasispecies detected with FLX sequencing.

Minority EBV sequence variants at a level of ≥10% were detected in two samples only. Sequence mixtures present at a ≥5% threshold revealed minority variants in 3.6% of investigated nucleotide positions (27/749 nucleotides sequenced,), increasing to 5.0% at a ≥2% cut-off (37/749 nucleotides,) and 8.3% at a ≥1% cut-off (62/749 nucleotides,). Samples 7, 8 and 13 did not have minority species present at ≥1%.

![](pone.0147567.t001){#pone.0147567.t001g}

  --------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------
  EBNA-1 aa pos   397       **410**   411       422       425       429       431       432       435       435       459       **459**   460       469       **473**   474       476       **484**   487       492       **499**   507       508       **520**   524       525       525       528       528       **529**   533       **534**   536       539       **549**   **550**   **553**   **559**   **561**   563       574       585       594       595       595
  B95-8 aa        R         G         E         G         G         V         P         G         E         E         R         R         K         R         G         S         P         G         A         S         D         V         F         L         T         A         A         I         I         P         L         T         L         L         P         Q         P         V         Y         M         V         T         R         V         V
  B95-8 codon     AGG       GGG       GAA       GGC       GGT       GTG       CCG       GGA       GAG       GAG       CGC       CGC       AAA       CGT       GGT       TCC       CCG       GGT       GCT       AGT       GAC       GTG       TTC       CTA       ACT       GCC       GCC       ATT       ATT       CCA       CTT       ACA       TTG       CTC       CCA       CAA       CCG       GTC       TAT       ATG       GTT       ACA       AGG       GTG       GTG
  EBNA-1 pos      1190      1231      1232      1265      1275      1286      1292      1296      1304      1305      1377      1378      1379      1406      1420      1421      1428      1453      1460      1475      1498      1520      1525      1561      1572      1574      1575      1583      1584      1588      1598      1603      1608      1616      1648      1651      1660      1678      1684      1690      1722      1754      1782      1785      1786
  variant aa      G         G         Q         S         S         M         T         V         stop      G         H         R         Q         S         G         T         Q         G         T         C         D         M         L         L         I         \$        \$        \$        T         P         I         T         S         I         P         Q         P         V         Y         I         G         P         K         A         A
  variant codon   **G**GG   GG**A**   **C**AA   **A**GC   G**A**T   **A**TG   **A**CG   G**T**A   **T**AG   GG**G**   C**A**C   CG**A**   **C**AA   **A**GT   GG**C**   **A**CC   C**A**G   GG**C**   **A**CT   **T**GT   GA**T**   **A**TG   TT**A**   CT**C**   A**T**T   **SS**C   **SS**C   **RY**T   A**C**T   CC**G**   **A**TT   AC**G**   **T**CG   **A**TC   CC**G**   CA**G**   CC**A**   GT**A**   TA**C**   AT**T**   G**G**T   **C**CA   A**A**G   G**C**G   GC**T**
  sample 1, 1%    AG                                                                                                  AG                                                                                                                                                                                            AG                                                                                        AT                                                CT         
  sample 1, 2%    AG                                                                                                                                                                                                                                                                                                AG                                                                                        AT                                                           
  sample 1, 5%    AG                                                                                                                                                                                                                                                                                                AG                                                                                                                                                     
  sample 1, 10%   AG                                                                                                                                                                                                                                                                                                AG                                                                                                                                                     
  sample 2, 1%                                                                                                                                                                                                                                                              CG        CG                                                AG        CT                                                                                                                       
  sample 3, 1%                                                                                              AG                  AC        AC                                                                                                                                                                                                                                    AG                                                                                         
  sample 3, 2%                                                                                                                            AC                                                                                                                                                                                                                                                                                                                               
  sample 3, 5%                                                                                                                            AC                                                                                                                                                                                                                                                                                                                               
  sample 4, 1%                                                                                                                                                                              CT                                                                                                                                                                                                                                                                             
  sample 4, 2%                                                                                                                                                                              CT                                                                                                                                                                                                                                                                             
  sample 5, 1%                        CG                            AG                                                                                        CT        AT        AC                  AG        AT        CT                            AC        CT                            AG                            AC                                                          AG                            GT        GT        AC        AG        CT         
  sample 5, 2%                        CG                            AG                                                                                        CT        AT        AC                  AG        AT        CT                            AC        CT                            AG                            AC                                                          AG                            GT        GT        AC        AG        CT         
  sample 5, 5%                        CG                            AG                                                                                        CT        AT        AC                  AG        AT        CT                            AC        CT                            AG                            AC                                                          AG                            GT        GT        AC        AG        CT         
  sample 5, 10%                                                     AG                                                                                        CT        AT        AC                  AG        AT        CT                            AC        CT                                                                                                                      AG                            GT        GT        AC        AG        CT         
  sample 6, 1%                                                                                                                                                                                                                                                                                                                                                        AG                                                                                                   
  sample 10, 1%                                                                                                                                               CT                                                                                                                                                                                                                                                                                                           
  sample 11, 1%                                                                                                                                               CT                                                                                                                                                                                                                                                                                                           
  sample 12, 1%             AG                                      AG                                                                                                            AC                  AG        AT        CT                            AC        CT                                                                                                                      AG                            GT        GT        AC        AG        CT         
  sample 12, 2%             AG                                      AG                                                                                                            AC                  AG        AT        CT                            AC        CT                                                                                                                      AG                            GT        GT        AC        AG        CT         
  --------------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- --------- ---------

  -------------------- --- --- --- ---- ---- ---- ---- ---- ---- --- --- --- --- ---- --- --- ---- --- ---- --- ---- ---- ---- ---- --- --- --- --- ---- --- --- --- --- ---- --- --- --- ---- --- ---- --- --- --- --- ----
  sample 12, 5%                              AG                                               AC       AG       CT             AC                                                                  GT                    
  sample 14, 1%                         AG                                                                                                          CT                                                                   
  B95-8, control 1%                AG             AC   GT   GT                   AC                                  AG   AC                                             AC               AC                            GT
  B95-8, control, 2%               AG                                                                                                                                                                                    
  -------------------- --- --- --- ---- ---- ---- ---- ---- ---- --- --- --- --- ---- --- --- ---- --- ---- --- ---- ---- ---- ---- --- --- --- --- ---- --- --- --- --- ---- --- --- --- ---- --- ---- --- --- --- --- ----

Subsequent capital letters indicate both nucleotide mixtures detected. Single capital letters indicate amino acids present. Amino acid positions representing silent mutations have been indicated in bold. EBNA-1 = Epstein-Barr virus nuclear antigen-1, aa = amino acid, pos = position

Sequence conservation and relevance to HLA-DRB1\*15 binding {#sec020}
-----------------------------------------------------------

As shown in [Fig 3](#pone.0147567.g003){ref-type="fig"}, EBNA-1 sequences were mapped against the standard reference strain B95-8 in order to illustrate known and putative HLA-DRB1\*15-restricted epitopes and their relationship with EBNA-1 sequence conservation at the amino acid level. This approach, which utilises the ConSeq server \[[@pone.0147567.ref053]\], reflects amino acid conservation in terms of the influence of physicochemical properties of amino acid substitution as well as the frequency of sequence variation. Hence, 'dips' in the conservation plot (highlighted in red) reflect sites of variation that are likely to influence protein structure. Above these plots, predicted HLA-DRB1\*15 binding sites are denoted along with the core binding regions, derived from NetMHCIIPan analysis \[[@pone.0147567.ref041]\]. As shown, this approach revealed two known HLA-DRB1\*1501 restricted epitopes (AEGLRALLARSHVER ('AEG': aa 481--496) and MVFLQTHIFAEVLKD ('MVF': aa 562--577), as well as two overlapping putative epitopes covering a region between positions 502--543. In contrast, no HLA-DRB1\*15 epitopes were identified within the N-terminal region of EBNA-1. The most frequent sequences at these epitope sites were AEGLR[**T**]{.ul}LLAR[**C**]{.ul}HVER and [**I**]{.ul}VFLQTHIFAE[**G**]{.ul}LKD (differences to B95-8 reference underlined). Variant sequences within these epitope regions are described in [Table 2](#pone.0147567.t002){ref-type="table"}, along with comparisons of HLA-DRB1\*15 binding affinity. As noted, there are no wild-type EBNA-1 variants within these known epitopes that would be predicted to abrogate HLA-DRB1\*15 binding completely, although further studies will be required to establish if minor variations in binding affinity could influence the nature of the T cell response, noting that a previous study has demonstrated both regulatory and effector EBNA-1-specific CD4^+^ T cells with identical epitope specificity \[[@pone.0147567.ref018]\]. Interestingly, eight of the nine polymorphic sites from the cluster analysis fell within our predicted HLA-DRB1 epitopes including two changes in the previously described 'AEG' and 'MVF' epitopes, respectively.

10.1371/journal.pone.0147567.t002

###### EBNA-1 sequence variation identified with next-generation sequencing technology, and impact on HLA-DRB1\*15 binding affinity within known epitopes.

The two most frequent variants for the A) AEG epitope and B) MVF epitope are printed in bold, the most frequent variant is underlined. All epitopes are predicted to be weak binders (affinity 50nM-500nM).

![](pone.0147567.t002){#pone.0147567.t002g}

  -------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ---------------------------- ----------- -------------- ----------- --------------
  **Table 2A**                                                                                                                          NetMHCII    NetMHCIIpan                
  nt B95-8       gca   gaa   ggt   tta   aga   gct   ctc   ctg   gct   agg   agt   cac   gta   gaa   agg   peptide                      core        affinity(nM)   core        affinity(nM)
  aa B95-8       A     E     G     L     R     A     L     L     A     R     S     H     V     E     R     AEGLRALLARSHVER              RALLARSHV   197            LRALLARSH   63
                 \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    **AEGLRALLARSHVER**          RALLARSHV   197            LRALLARSH   63
                 \-    \-    \-    \-    \-    V     \-    \-    \-    \-    \-    \-    \-    \-    \-    AEGLRVLLARSHVER              RVLLARSHV   87             LRVLLARSH   61
                 \-    \-    \-    \-    K     \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    AEGLKALLARSHVER              KALLARSHV   165            LKALLARSH   88
                 \-    \-    \-    \-    \-    T     \-    \-    \-    \-    C     \-    \-    \-    \-    [**AEGLRTLLARCHVER**]{.ul}   LRTLLARCH   267            LRTLLARCH   91
                 \-    \-    \-    \-    \-    A     \-    \-    \-    \-    S     \-    \-    \-    \-    AEGLRALLARSHVER              RALLARSHV   197            LRALLARSH   63
  pos B95-8      482   483   484   485   486   487   488   489   490   491   492   493   494   495   496                                                                        
  **Table 2B**                                                                                                                          NetMHCII    NetMHCIIpan                
  nt B95-8       atg   gtc   ttt   tta   caa   act   cat   ata   ttt   gct   gag   gtt   ttg   aag   gat   peptide                      core        affinity(nM)   Core        affinity(nM)
  aa B95-8       M     V     F     L     Q     T     H     I     F     A     E     V     L     K     D     MVFLQTHIFAEVLKD              MVFLQTHIF   303            VFLQTHIFA   257
                 \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    **MVFLQTHIFAEVLKD**          MVFLQTHIF   303            VFLQTHIFA   257
                 I     \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    G     \-    \-    \-    [**IVFLQTHIFAEGLKD**]{.ul}   IVFLQTHIF   261            IVFLQTHIF   259
                 \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    F     \-    \-    MVFLQTHIFAEVFKD              VFLQTHIFA   281            VFLQTHIFA   270
                 I     \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    V     \-    \-    \-    IVFLQTHIFAEVLKD              IVFLQTHIF   275            IVFLQTHIF   181
                 M     \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    G     \-    \-    \-    MVFLQTHIFAEGLKD              VFLQTHIFA   272            MVFLQTHIF   386
                 M     \-    \-    \-    \-    \-    \-    \-    \-    \-    \-    V     \-    \-    \-    MVFLQTHIFAEVLKD              MVFLQTHIF   303            VFLQTHIFA   257
  pos B95-8      563   564   565   566   567   568   569   570   571   572   573   574   575   576   577                                                                        
  -------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ---------------------------- ----------- -------------- ----------- --------------

nt: nucleotides, aa: amino acid, pos: amino acid position, B95-8: wildtype EBV reference strain

Identification of HLA-DRB1\*15 epitopes within brain proteins homologous to EBNA-1 {#sec021}
----------------------------------------------------------------------------------

For this analysis we utilised three datasets enriched for CNS proteins \[[@pone.0147567.ref042]\], to identify candidate cross-reactive proteins that shared a propensity for HLA-DRB1\*15 binding as well as homology to natural EBNA-1 sequences at these sites. This analysis was predicated on the hypothesis that (1) EBNA-1-specific T cell immunity reflects a standard model of HLA-restricted binding and antigen presentation, providing a long-term stimulus for T cell responses that could then (2) cross-react with CNS-specific antigens in a manner that requires HLA-restricted presentation but which may be less predictably associated with HLA binding affinity given the constraints of negative selection against high-affinity autoantigens, and the known altered topology of many autoreactive HLA-peptide-TCR interactions \[[@pone.0147567.ref054]\]. This approach is also informed by the previous demonstration of EBNA-1-specific CD4^+^ T cells capable of producing pro-inflammatory responses against myelin antigens in a seminal study by Lunemann and colleagues \[[@pone.0147567.ref033]\].

Thus, we initially selected EBNA-1 epitopes of interest based on HLA binding affinity, and then identified candidate CNS protein epitopes that would be predicted to bind HLA-DRB1\*15 with sufficient affinity to allow antigen presentation (strong and weak binders with affinity threshold 500 nM) and which exhibited homology with the EBNA-1 epitope (threshold ≥3 residues within the 9 amino acid core binding region identified by NetMHCII and NetMHCIIPan analysis). Applying this approach to myelin proteins of known interest in MS research in the first instance reviewed in \[[@pone.0147567.ref055]\], we identified potential cross-reactive responses involving a number of major myelin antigens ([Table 3](#pone.0147567.t003){ref-type="table"}) including experimentally confirmed HLA-DRB1\*15-restricted epitopes associated with encephalitogenic T cell responses (asterisked) including 2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase, alpha B crystallin, myelin basic protein and oligodendrocyte-specific protein. Additionally, we identified several novel candidate antigens within glial fabrillary acidic protein, myelin proteolipid protein, neurofilament heavy polypeptide and myelin-oligodendrocyte glycoprotein.

10.1371/journal.pone.0147567.t003

###### Putative HLA-DRB1\*15 binders within autologous EBNA-1 peptide sequences and candidate myelin antigens.

![](pone.0147567.t003){#pone.0147567.t003g}

  Brain Peptides                                                     EBNA-1 Peptides          Peptide Match Count   Brain Binding Scores   EBNA-1 Binding Scores   EBNA-1 Protein Position   Brain Protein Position   Brain Protein Accession No(s)
  ------------------------------------------------------------------ ------------------------ --------------------- ---------------------- ----------------------- ------------------------- ------------------------ -------------------------------
  GKLYSL[GNGRWMLTL]{.ul}                                             GSKTSL[YNLRRGTTL]{.ul}   X...XX.X.X...XX       66                     267                     512                       370                      P09543
  RGK[LYSLGNGRW]{.ul}MLT                                             GGS[KTSLYNLRR]{.ul}GVA   .X...XX.X.X\....      41                     347                     511                       369                      P09543
  [LYSLGNGRWMLTLAK]{.ul} [\*](#t003fn002){ref-type="table-fn"}       KTSL[YNLRRGVAL]{.ul}AI   ..XX.X.X\....XX.      306                    45                      514                       372                      P09543
  [SRGKLYSLGNGRWML]{.ul} [\*](#t003fn002){ref-type="table-fn"}       SKTSL[YNLRRGVAL]{.ul}A   X...XX.X..X\....      41                     90                      513                       368                      P09543
  [LSPFYLRPPSFLRAP]{.ul} [\*\*](#t003fn003){ref-type="table-fn"}     TSL[YNLRRGVAL]{.ul}AIP   .X...XX\....X..X      47                     52                      514                       44                       ACP18852
  [LSPFYLRPPSFLRAP]{.ul} [\*\*](#t003fn003){ref-type="table-fn"}     TSL[YNLRRGTAL]{.ul}AIP   .X...XX\....X..X      135                    16                      515                       44                       ACP18852
  [SPFYLRPPSFLRAPS]{.ul}                                             SLYN[LRRGVALAI]{.ul}PQ   X...XX\....X..X.      59                     54                      515                       45                       AAB23453
  [KTKEGVLYVGSKTRE]{.ul}                                             WVAG[VFVYGGSKT]{.ul}SL   \...\....X.XXXX..     54                     8                       503                       32                       Q16143
  [EKTKEGVLYVGSKTR]{.ul}                                             NWVAGV[LVYGGSKTS]{.ul}   \...\.....X.XXXX.     67                     48                      502                       31                       Q16143
  [TRLSLARMPPPLPTR]{.ul}                                             L[RVLLARSHV]{.ul}ERTTE   .X..XXX\...\...X.     468                    32                      485                       35                       P14136
  [KLALDIEIATYRKLL]{.ul}                                             NLRRG[IGLAIPQCL]{.ul}L   .X...X..X\....XX      176                    323                     518                       356                      P14136
  [GKGRGLSLSRFSWGA]{.ul}                                             PQ[CRITPLSRL]{.ul}PFGM   ...X...XXX...X.       287                    384                     528                       131                      AAC41944
  [EFAPVLLLESHCAAA]{.ul} [\*\*\*](#t003fn004){ref-type="table-fn"}   G[LRVLLARSH]{.ul}VERTT   XX\...\...XX\....X    410                    125                     483                       79                       AAC41944
  [PGVLVLLAVLPVLLL]{.ul}                                             EGL[RVLLARSHV]{.ul}ERT   .X..XXXX...X...       301                    8                       483                       153                      Q16653
  [GPLVALIICYNWLHR]{.ul}                                             GP[LRESIVCYF]{.ul}IVFL   XXX...X.XX\.....      26                     373                     551                       219                      Q16653
  [GEGKVTLRIRNVRFS]{.ul}                                             AE[GLRTLLARC]{.ul}HVXR   .XX..XX..X\.....      89                     16                      482                       106                      Q16653
  [DPFYWVSPGVLVLLA [†](#t003fn005){ref-type="table-fn"}]{.ul}        QKFEN[IAXGLRTLL]{.ul}A   ..X\.....X...XXX      134                    202                     475                       146                      Q16653
  [DPFYWVSPGVLVLLA [†](#t003fn005){ref-type="table-fn"}]{.ul}        PKFEN[IAEGLKLLL]{.ul}A   ..X\.....X...XXX      185                    438                     475                       146                      Q16653
  [CSAVPVYIYFNTWTT]{.ul}                                             VAG[VFVYGGXNT]{.ul}SLY   ...X.XX...XX...       31                     8                       504                       169                      AAA59565
  [ATYNFAVLKLMGRGT]{.ul}                                             GTWVAG[VLVYGGSKT]{.ul}   .X\....XX...X..X      219                    8                       501                       261                      AAA59565
  [LLTFMIAATYNFAVL]{.ul}                                             [LVMTKPAPT]{.ul}CNIKVT   X\.....X.X.X..X.      70                     32                      582                       254                      AAA59565
  [EEITEYRRQLQARTT]{.ul}                                             ENIAEG[LRVLLARSH]{.ul}   X.X.X..X.X.XX..       376                    239                     479                       316                      P12036
  [EMRGAVLRLGAARGQ]{.ul}                                             ENIAEG[LRLLLARCH]{.ul}   X\.....XXX..XX..      138                    154                     479                       152                      P12036
  [GAVLRLGAARGQLRL]{.ul}                                             AEG[LRLLLARCH]{.ul}VER   ...XXX..XX\.....      67                     88                      482                       155                      P12036
  [TRLSFTSVGSITSGY]{.ul}                                             VAG[VFVYGGSRT]{.ul}SLY   \....X...XX.XX.X      206                    71                      504                       398                      P07196
  [KVVLIKNTLRSLEVL]{.ul}                                             KFEN[IAEGLRLLL]{.ul}AR   X...X...XX.X...       74                     336                     477                       137                      P23515
  [SLEVLNLSSNKLWTV]{.ul}                                             G[LRVLLARSH]{.ul}VERTT   .X.XX...X\....X.      62                     125                     484                       147                      P23515
  [PGTLINLTNLTHLYL]{.ul}                                             KTSL[YNLRRGTAL]{.ul}AI   ...X.XX...X.X..       102                    77                      514                       184                      P23515
  [ENVSTTLRALAPRLM]{.ul}                                             EN[IAEGLRALL]{.ul}ARSH   XX\....XXXX..X..      39                     32                      479                       187                      AAC25187
  [AGVLLILLALCALVA]{.ul}                                             AEG[LRTLLARCH]{.ul}VER   X..X..XXX.X\....      389                    32                      482                       123                      AAC25187
  [NVSTTLRALAPRLMR]{.ul}                                             NIAE[GLRALLARS]{.ul}HV   X\....XXXX..X...      25                     16                      480                       188                      AAC25187
  [CKPLVDILILPGYVQ [††](#t003fn006){ref-type="table-fn"}]{.ul}       IKD[LVMIKPAPT]{.ul}CNI   .X.XX.X...X\....      48                     120                     578                       65                       AAC25187
  [ELEKAMVALIDVFHQ]{.ul}                                             EGL[KALLARSHV]{.ul}ERT   X..XX..X...X...       376                    16                      483                       3                        NP_006263
  AFV[AMVTTACHE]{.ul}FFE                                             VCY[FMVFLQTHI]{.ul}FAE   \....XX\....X.X.X     457                    71                      558                       76                       NP_006263
  F[GAEILKKIP]{.ul}GRVST                                             N[IAEGLKALL]{.ul}ARSHV   ..XX.XX\....X...      51                     16                      480                       91                       NP_006746
  G[IRKFAADAV]{.ul}KLERM                                             N[LRRGIALAV]{.ul}QQCRL   ..X...X.XX...X.       387                    32                      519                       311                      NP_006746
  PIL[AVLLFSSLV]{.ul}LSP                                             EGL[RVLLARSHV]{.ul}ERT   ..X.XXX..X.X...       66                     8                       483                       12                       P25189
  IL[AVLLFSSLV]{.ul}LSPA                                             GL[RVLLARSHV]{.ul}ERTT   .X.XXX..X.X\....      65                     16                      484                       13                       P25189
  EFA[PVLLLESHC]{.ul}AAA                                             EGL[RVLLARSHV]{.ul}ERT   X...XXX..XX\....      177                    8                       483                       410                      P20916
  VEFA[PVLLLESHC]{.ul}AA                                             AEGL[RVLLARSHV]{.ul}ER   .X...XXX..XX...       250                    16                      482                       409                      P20916
  PGV[LVLLAVLPV]{.ul}LLL                                             EGL[RVLLARSHV]{.ul}ERT   .X..XXXX...X...       301                    8                       483                       153                      Q16653
  V[LGPLVALII]{.ul}CYNWL                                             N[LRRGVALAI]{.ul}PQCRL   .X...XXX.X\....X      148                    32                      519                       217                      Q16653
  GAEIRH[VLVTLGEKM]{.ul}                                             GTWVAG[VLVYGGSKT]{.ul}   X\.....XXX..X.X.      358                    8                       501                       106                      P60660
  K[LRRGDLPFV]{.ul}VPRRM                                             N[LRRGIALAV]{.ul}QQCRL   .XXXX\....X...X.      498                    32                      519                       1920                     P35579
  AEE[LRARLTAKK]{.ul}QEL                                             AEG[LRALLARSH]{.ul}VER   XX.XXX.X\.....X.      466                    115                     482                       899                      P35579

Underlined is the core of the peptide. Binding score (nM) prediction using NetMHCII and NetMHCIIpan. Binding score \<50: strong binder, binding score 50--500 weak binder.

\*Known CNP epitope \[[@pone.0147567.ref056]\]

\*\*Known aB-crystallin epitope \[[@pone.0147567.ref057]\]

\*\*\*Known MBP epitope \[[@pone.0147567.ref058]\]

†Known MOG epitope \[[@pone.0147567.ref059]\]

††Known OSP epitope \[[@pone.0147567.ref060]\].

We then extended this analysis to a larger set of central nervous system antigens enriched for axoglial proteins that maintain myelinated nerves and nodes of Ranvier critical for saltatory conduction reviewed in \[[@pone.0147567.ref061]\], noting recent evidence that the axoglial apparatus may be targeted in the earliest phases of multiple sclerosis lesion development \[[@pone.0147567.ref062],[@pone.0147567.ref063]\]. As described in [Table 4](#pone.0147567.t004){ref-type="table"}, which presents a subset of results based on optimal EBNA-1 epitope binding and core match values ≥3, this analysis identified a larger set of potentially cross-reactive CNS proteins including neurofascin \[[@pone.0147567.ref062]\] as well as a number of other proteins involved in actin organisation and paranodal assembly like ankyrins, contactin-associated proteins as well as gelsolin \[[@pone.0147567.ref064]\].

10.1371/journal.pone.0147567.t004

###### Extended axoglial brain protein dataset with HLA-DRB1\*1501 predicted brain epitopes overlapping with predicted EBV binders.

![](pone.0147567.t004){#pone.0147567.t004g}

  Brain Peptides           EBNA-1 Peptides          Peptide Match Count   Brain Binding Scores   EBNA-1 Binding Scores   EBNA-1 Protein Position   Brain Protein Position   Brain Protein Accession No(s)   Brain Protein Genbank Description(s)
  ------------------------ ------------------------ --------------------- ---------------------- ----------------------- ------------------------- ------------------------ ------------------------------- ------------------------------------------------------
  TG[QFVYCGKKA]{.ul}QLNI   AG[VFVYGGSKT]{.ul}SLYN   .X.XXX.X.X..X..       203                    8                       505                       84                       P62917                          60S ribosomal protein L8
  G[QFVYCGKKA]{.ul}QLNIG   GV[FVYGGSKT]{.ul}SLYNL   X.XXX.X.X..X...       237                    8                       506                       85                       P62917                           
  [QFVYCGKKA]{.ul}QLNIGN   VF[VYGGSKT]{.ul}SLYNLR   .XXX.X.X..X\....      302                    16                      507                       86                       P62917                           
  [GDRGKLARA]{.ul}SGNYAT   [GLRTLLARC]{.ul}HVERTT   X.X..XXX\...\...X     329                    32                      484                       121                      P62917                           
  R[EEIHEYRRQ]{.ul}LQART   F[ENIAEGLRV]{.ul}LLARS   .X.X.X..X.X.XX.       231                    32                      478                       309                      Q16352                          Alpha-internexin
  EEIHE[YRRQLQART]{.ul}I   ENIAE[GLRTLLARC]{.ul}H   X.X.X..X.X.XX..       189                    32                      479                       310                      Q16352                           
  VAEL[LATLQASSQ]{.ul}AA   IAEG[LRTLLARSH]{.ul}VE   .XX.X.XX.X.X...       348                    280                     480                       235                      Q16352                           
  VAS[VLLEAGAAH]{.ul}SLA   VAG[VLVYGGSKT]{.ul}SLY   XX.XX...X...XX.       140                    22                      504                       545                      Q01484                          Ankyrin-2
  DVAS[VLLEAGAAH]{.ul}SL   WVAG[VLVYGGSKT]{.ul}SL   .XX.XX...X...XX       178                    29                      503                       544                      Q01484                           
  ELLLER[GAPLLARTK]{.ul}   ENIAEG[LRPLLARCH]{.ul}   X...X...XXXXX..       112                    408                     479                       316                      Q01484                           
  RIT[CRLVKPQK]{.ul}LSTP   RRG[IGLAIPQCL]{.ul}LTP   X\....X..XX.X.XX      227                    369                     520                       948                      AAA51732                         
  DIVKLL[LPRGGSPHS]{.ul}   NWVAGV[LVYGGSKTS]{.ul}   ..X...X..XXX..X       74                     48                      502                       583                      AAA51732                         
  G[AYVKLLSKT]{.ul}PELNL   G[VLVYGGSKT]{.ul}SLYNL   X..X...XXX...XX       283                    30                      506                       162                      P27824                          Calnexin
  TAEAI[KALGAKHCV]{.ul}K   IAEGL[KALLARSHV]{.ul}E   .XX..XXX.X...X.       69                     16                      481                       209                      P30042                          ES1 protein homolog, mitochondrial
  AEAI[KALGAKHCV]{.ul}KE   AEGL[KALLARSHV]{.ul}ER   XX..XXX.X...X..       73                     16                      482                       210                      P30042                           
  LSGESL[GHLRSLGAL]{.ul}   GSKTSL[YNLRRGVAL]{.ul}   .X..XX..XX...XX       406                    16                      512                       189                      P0C6S8                          Leucine-rich repeat and immunoglobulin-like
  SGESL[GHLRSLGAL]{.ul}R   SKTSL[YNLRRGVAL]{.ul}A   X..XX..XX...XX.       54                     16                      513                       190                      P0C6S8                           
  LSGESL[GHLRSLGAL]{.ul}   GSKTSL[YNLRRGIAL]{.ul}   .X..XX..XX...XX       406                    16                      512                       189                      P0C6S8                           
  AFLGLR[QIRLLNLSN]{.ul}   VALAIP[QCRLTPLSR]{.ul}   ..X...X.XX..XX.       34                     32                      524                       313                      P0C6S8                           
  LGLR[QIRLLNLSN]{.ul}NL   LAVQ[QCRLTPLSR]{.ul}LP   X...X.XX..XX...       26                     32                      526                       315                      P0C6S8                           
  AG[VLLILLALC]{.ul}ALVA   AE[GLRTLLARC]{.ul}HVXR   X..X..XXX.X\....      389                    16                      482                       123                      NP_005593                       claudin-11 isoform 1
  [VLLILLALC]{.ul}ALVATI   [GLRTLLARC]{.ul}HVERTT   .X..XXX.X\....X.      349                    32                      484                       125                      NP_005593                        
  LYC[IYVAIGQKR]{.ul}STV   RRG[IALAIPQCR]{.ul}LTP   ...X..XX.X.X.X.       124                    32                      521                       242                      P25705                          ATP synthase subunit alpha, mitochondrial
  SPGW[LADGSVRYP]{.ul}IV   QPGP[LRESIVCYF]{.ul}IV   .XX.X\....X.X.XX      398                    361                     550                       302                      Q96GW7                          Brevican core protein
  L[LGRWKALLIPPSSP]{.ul}   N[LRRGIALAI]{.ul}PQCXL   .X.X..XX.XX\....      78                     32                      519                       893                      Q96GW7                           
  ED[SLECLRAML]{.ul}SANI   EN[IAEGLRALL]{.ul}ARSH   X...X.XXX.X\....      105                    32                      479                       661                      Q00610                          Clathrin heavy chain 1
  SLEC[LRAMLSANI]{.ul}RQ   SLYN[LRRGISLAI]{.ul}PQ   XX..XX...X..X.X       38                     77                      516                       663                      Q00610                           
  G[VLLILLALC]{.ul}ALVAT   E[GLRTLLARC]{.ul}HVERT   ..X..XXX.X\....X      387                    32                      483                       124                      O75508                          Claudin-11
  [VLLILLALC]{.ul}ALVATI   [GLRTLLARC]{.ul}HVERTT   .X..XXX.X\....X.      349                    32                      484                       125                      O75508                           
  EN[LIVPGGVKT]{.ul}IEAN   AG[VFVYGGSKT]{.ul}SLYN   \....X.XX.XX...X      318                    8                       505                       47                       Q14194                          Dihydropyrimidinase-related protein 1
  DN[LIVPGGVKT]{.ul}IEAN   AG[VLVYGGSKT]{.ul}SLYN   \....X.XX.XX...X      351                    24                      505                       47                       Q14195                           
  E[LRREISYAI]{.ul}KNIHG   N[LRRGIALAI]{.ul}PQCXL   .XXX.X..XX\.....      74                     32                      519                       383                      Q05193                          Dynamin-1
  KE[LRREISYAI]{.ul}KNIH   YN[LRRGISLAI]{.ul}PQCR   ..XXX.XX.XX\....      116                    237                     518                       382                      Q05193                           
  DEKE[LRREISYAI]{.ul}KN   SLYN[LRRGISLAI]{.ul}PQ   \....XXX.XX.XX..      246                    77                      516                       380                      Q05193                           
  EDLRRG[LVMVKPGSI]{.ul}   KDAIKD[LVMTKPAPT]{.ul}   .X\....XXX.XX...      162                    32                      576                       332                      P49411                          Elongation factor Tu, mitochondrial
  DLRRG[LVMVKPGSI]{.ul}K   DGIKD[LVMTKPAPT]{.ul}C   X\....XXX.XX\....     93                     32                      577                       333                      P49411                           
  [IVFRGEHGF]{.ul}IGCRKV   [IVFLQTHIF]{.ul}AEGLKX   XXX...X.X\....X.      233                    16                      563                       386                      Q16658                          Fascin
  [IVFRGEHGF]{.ul}IGCRKV   [IVFLQTHIF]{.ul}XEGLKD   XXX...X.X\....X.      233                    32                      563                       386                      Q16658                           
  TGAQE[LLRVLRAQP]{.ul}V   ENIAE[GLRVLLARS]{.ul}H   \....X.XXXX.X...      52                     32                      479                       616                      P06396                          Gelsolin
  GDS[YIILYNYRH]{.ul}GGR   GGS[KTSLYNLRR]{.ul}GVA   X.X...XXX.X.X..       11                     347                     511                       471                      P06396                           
  KVKAH[GKKVLGAFS]{.ul}D   ENIAE[GLRVLLARS]{.ul}H   ...X.X..XX.X.X.       498                    32                      479                       60                       P68871                          Hemoglobin subunit beta
  AFLGLR[QIRLLNLSN]{.ul}   VALAIP[QCRLTPLSR]{.ul}   ..X...X.XX..XX.       34                     32                      524                       313                      P0C6S8                          Leucine-rich repeat and immunoglobulin-like
  LGLR[QIRLLNLSN]{.ul}NL   LAVQ[QCRLTPLSR]{.ul}LP   X...X.XX..XX...       26                     32                      526                       315                      P0C6S8                           
  YSWGMA[VNVYSTSIT]{.ul}   GNWVAG[VLVYGGSKT]{.ul}   ..X...X.XX..X.X       239                    8                       501                       40                       Q15555                          Microtubule-associated protein RP/EB family member 2
  WGMA[VNVYSTSIT]{.ul}QE   WVAG[VFVYGGSKT]{.ul}SL   X...X.XX..X.X..       252                    8                       503                       42                       Q15555                           
  L[PRWQLALAV]{.ul}GAPLL   N[LRRGIALAV]{.ul}QQCRL   ..X...XXXX\....X      97                     32                      519                       36                       O94826                          Mitochondrial import receptor subunit TOM70
  IFQ[KLMFKNAPT]{.ul}PQE   IKD[LVMTKPAPT]{.ul}CNI   X\....X.X.XXX...      90                     16                      579                       114                      P13591                          Neural cell adhesion molecule 1
  VKIFQ[KLMFKNAPT]{.ul}P   DAIKD[LVMTKPAPT]{.ul}C   ..X\....X.X.XXX.      40                     32                      577                       112                      P13591                           
  SLLV[TRLQKALGV]{.ul}RQ   SLYN[LRRGIALAV]{.ul}QQ   XX...X...XX.X.X       121                    57                      516                       5                        Q99798                          Aconitate hydratase, mitochondrial
  SLLV[TRLQKALGV]{.ul}RQ   SLYN[LRRGIALAV]{.ul}SQ   XX...X...XX.X.X       121                    58                      516                       5                        Q99798                           
  SLLV[TRLQKALGV]{.ul}RQ   SLYN[LRRGIALAV]{.ul}PQ   XX...X...XX.X.X       121                    72                      516                       5                        Q99798                          Aconitate hydratase, mitochondrial
  NKG[IGLAIVRDL]{.ul}CRL   RRG[IGLAIPQCL]{.ul}LTP   ..XXXXXX...X...       436                    369                     521                       14                       P16152                          Carbonyl reductase NADPH 1
  [RRGRLAVSF]{.ul}RFRTWD   [LRALLARSH]{.ul}VERTTD   .X..XX.X...XX.X       77                     407                     485                       379                      P78357                          Contactin-associated protein 1
  [LGAALRRCA]{.ul}VAATTR   [LRLLLARCH]{.ul}VERTTE   X...X.XX.X..XX.       401                    277                     485                       2                        P20674                          Cytochrome c oxidase subunit 5A, mitochondrial
  [LGAALRRCA]{.ul}VAATTR   [LRTLLXRCH]{.ul}VERTTX   X...X.XX.X..XX.       401                    248                     484                       2                        P20674                           
  G[TRLSLARMP]{.ul}PPLPT   G[LRLLLARCH]{.ul}VERTT   X.XX.XXX\...\...X     326                    139                     484                       34                       P14136                          Glial fibrillary acidic protein
  VVF[FNVPEKLRL]{.ul}PDA   QKFENIAEGLRLLLA          ..X.X..X.XXX..X       416                    382                     476                       134                      P78559                          Microtubule-associated protein 1A
  TAYA[RLRGIEQAV]{.ul}QS   SLYN[LRRGIALAV]{.ul}QQ   ..X...XXX..XXX.       482                    57                      516                       541                      Q16891                          Mitochondrial inner membrane protein
  NTA[YARLRGIEQ]{.ul}AVQ   TSL[YNLRRGIAL]{.ul}AVQ   ...X...XXX..XXX       349                    63                      515                       540                      Q16891                           
  FT[LKVLTTRGV]{.ul}AERT   EG[LRVLLARSH]{.ul}VERT   ..X.XX..X...XXX       209                    113                     483                       229                      O94856                          Neurofascin
  TL[KVLTTRGVA]{.ul}ERTP   GL[KLLLARSHV]{.ul}ERTT   .XX.X..X...XXX.       368                    96                      484                       230                      O94856                           
  FTL[KVLTTRGVA]{.ul}ERT   EGL[KLLLARSHV]{.ul}ERT   ..XX.X..X...XXX       209                    87                      483                       229                      O94856                           
  PTEI[IAFSNRAED]{.ul}FR   KFEN[IADSLRALL]{.ul}AR   ..X.XX.X.XX...X       83                     436                     477                       52                       P32119                          Peroxiredoxin-2
  EIIAFS[NRAEDFRKL]{.ul}   ENIADS[LRALLARSH]{.ul}   X.XX.X.XX...X..       233                    194                     479                       54                       P32119                           
  GSVILL[ENLRFHVEE]{.ul}   GSKTSL[YNLRRGVAL]{.ul}   XX...X.XXX..X..       33                     119                     512                       114                      P00558                          Phosphoglycerate kinase 1
  AGS[VILLENLRF]{.ul}HVE   GGS[KTSLYNLRR]{.ul}GVA   .XX...X.XXX..X.       26                     347                     511                       113                      P00558                           
  ASL[QRVRRPVAM]{.ul}VMP   TSL[YNLRRGVAL]{.ul}AIP   .XX...XX.XX...X       268                    52                      515                       95                       Q15149                          Plectin
  LKKG[LLSAEVARL]{.ul}LL   SQKF[ENIAEGLRL]{.ul}LL   ..X\....XX..XXXX      70                     465                     475                       3847                     Q15149                           
  VRV[FRIFKLSRH]{.ul}SKG   VPQ[CRITPLSRL]{.ul}PFG   X...XX..XXX...X       13                     475                     528                       299                      P16389                          Potassium voltage-gated channel subfamily A member 2
  VRV[FRIFKLSRH]{.ul}SKG   VSQ[CRITPLSRL]{.ul}PFG   X...XX..XXX...X       13                     427                     528                       299                      P16389                           
  LFPG[VALLLAAAR]{.ul}LA   LRRG[VALAIPQCR]{.ul}LT   X..XXXX\.....XX.      131                    413                     520                       8                        P30101                          Protein disulfide-isomerase A3
  ALFPG[VALLLAAAR]{.ul}L   NLRRG[VALAIPQCRL]{.ul}   .X..XXXX\.....XX      242                    333                     519                       7                        P30101                           
  PAIRLL[YAKRPGIGL]{.ul}   GSRTSL[YNLRRGIGL]{.ul}   \.....XX..X.XXXX      40                     250                     512                       190                      O75061                          Putative tyrosine-protein phosphatase auxilin
  RLL[YAKRPGIGL]{.ul}SPS   TSL[YNLRRGIAL]{.ul}AVS   ..XX..X.XX.X..X       466                    64                      515                       193                      O75061                           
  SFASD[PILYRPVAV]{.ul}A   SKTSL[YNLRRGVAL]{.ul}A   X..X...X.X.XX.X       253                    90                      513                       97                       P14618                          Pyruvate kinase PKM
  VEG[SFVYKGGKI]{.ul}YKV   VAG[VFVYGGSKT]{.ul}SLY   X.X.XXX.X.X\....      120                    100                     504                       105                      P31150                          Rab GDP dissociation inhibitor alpha
  ARK[KKLLEAQSH]{.ul}FRK   AEG[LKLLLARSH]{.ul}VER   X...XXX.X.XX...       212                    86                      482                       2074                     Q13813                          Spectrin alpha chain, non-erythrocytic 1
  TTCIEL[GKSLLARKH]{.ul}   ENIAEG[LKLLLARSH]{.ul}   \....X..X.XXXX.X      62                     254                     479                       1968                     Q01082                           

Underlined is the core of the peptide. Binding score (nM) prediction using NetMHCII and NetMHCIIpan. Binding score \<50: strong binder, binding score 50--500 weak binder.

Discussion {#sec022}
==========

In this study we have proven the feasibility of obtaining EBNA-1 sequences directly from buffy coat samples, without any requirement for primary cultures that could theoretically be associated with preferential selection of viral sequence variants through *ex vivo* expansion. In this regard our findings are in keeping with those of Burrows and colleagues \[[@pone.0147567.ref011]\], who demonstrated similar patterns of EBNA-1 sequence variation predominantly within the C-terminal region in both MS cases and controls, in a study that did involve primary B lymphocyte cultures. Both studies, as well as a more recent analysis of spontaneously outgrown human lymphoblastoid cell lines \[[@pone.0147567.ref065]\] are in agreement in demonstrating that the majority of autologous sequences do not align closely with the widely used B95-8 laboratory strain--a result that is perhaps not surprising given that this strain was originally identified following transfusion-associated EBV in an elderly woman and subsequently selected for its ability to efficiently immortalise B lymphocytes \[[@pone.0147567.ref066]\].

Our results are also in agreement with other studies that have identified similar patterns of EBNA-1 \[[@pone.0147567.ref067]\] and EBNA-2 \[[@pone.0147567.ref068]\] sequence variation when comparing MS cases and controls, albeit at low resolution in these cases, suggesting that MS susceptibility is not likely to be readily explained by an 'encephalitogenic strain' of EBV. We have also explored sequence variation within individual samples using next-generation sequencing techniques, to investigate if the presence of multiple viral sequence variants could indicate sites of immune selection pressure--as has been suggested previously for EBNA-1 \[[@pone.0147567.ref011]\]--and/or that infection with multiple EBV strains could represent a risk factor for MS disease as has been previously proposed \[[@pone.0147567.ref069]\]. We identified nucleotide mixtures present at 10 percent in two samples. Mixtures were primarily caused by point mutations leading to amino acid changes in 12 different positions compared to silent mutations in five positions only. This could indicate EBV superinfection or viral immune escape. While we were able to identify low-level EBNA-1 sequence variation in these samples (involving 8.3% of nucleotides at a 1% threshold), our results do not support a strong influence of intraindividual EBV sequence variation in MS disease risk and we cannot exclude that some of these point mutations are due to technical artefacts. It is however interesting to note that EBNA-1 sequence conservation described in [Fig 4](#pone.0147567.g004){ref-type="fig"} (reflecting genetic variation as well as the impact this has on amino acid properties), does appear to map to HLA-DRB1 binding regions, although we were unable to identify natural sequence variants that were associated with abrogation of HLA binding using the NetMHCIIPan prediction algorithm. However, in the HLA-viral sequence variation association analyses, we could identify eight out of nine EBNA-1 polymorphic nucleotide positions significantly associated with MS risk alleles within these HLA-DRB1 binding regions, including two in the previously described HLA-DRB1\*15 'AEG' and 'MVF' epitopes respectively, noting in each case that the more common (wild-type) viral sequence was favoured in the presence of disease-associated HLA-DR alleles. These differences will be explored further in terms of their impact on epitope-specific CD4^+^ T-cell immune responses, acknowledging in relation to MS pathogenesis that important differences may relate to the selection of regulatory versus effector EBNA-1-specific CD4+ T cells \[[@pone.0147567.ref018]\], rather than simply reflecting immune evasion.

![EBNA-1 sequence conservation and relationship to NetMHCII predicted HLA-DRB1\*DR15-restricted epitopes derived from patient MS sequences.\
Shown are EBNA-1 amino acid positions 473--593. Predicted epitopes: blue boxes, known epitopes: black underlined, predicted epitope core: grey shade.](pone.0147567.g004){#pone.0147567.g004}

We have also explored the potential for autoantigens to be selected by cross-reactive EBNA-1-specific T cells, according to a shared propensity for HLA-DRB1\*15-restricted antigen presentation as well as evidence of sequence homology. This concept is in keeping with previous experimentally-proven examples of this phenomenon (albeit without identification of specific epitopes involved) \[[@pone.0147567.ref035]\], with additional support from observations that HLA-DRB1\*15-restricted immune responses are characterised by a relatively high level of TCR degeneracy that would favour cross-reactivity \[[@pone.0147567.ref070]\]. These results are preliminary and require experimental confirmation of their functional validity.The main purpose of this analysis was to create a platform for experimental design that acknowledges natural patient derived EBNA-1 sequence variants as the basis for epitope selection, while also expanding the possibilities of identifying novel candidate CNS antigens that may have a role in MS pathogenesis. As noted by Ben-Nun and colleagues \[[@pone.0147567.ref055]\] and Lassmann and colleagues \[[@pone.0147567.ref071]\], MS research is increasingly moving away from reductionist experimental models towards an interest in a wide array of myelin and axoglial antigen targets, which would be in keeping with a model of MS pathogenesis that allows for cross-reactive T cell (as well as humoral) responses that are initially driven by viral-specific responses--with EBNA-1 representing a legitimate candidate target based on previous work \[[@pone.0147567.ref027], [@pone.0147567.ref031]--[@pone.0147567.ref039]\].

These observations, along with continuing evidence of patient-specific heterogeneity of MS lesion pathology \[[@pone.0147567.ref072]\] and oligoclonal TCR repertoire \[[@pone.0147567.ref073]\] would support a model of MS disease pathogenesis in which virus-specific immunity, which is oligoclonal in nature as determined by viral sequence variation seen in this and other studies \[[@pone.0147567.ref009]--[@pone.0147567.ref011]\] as well as by polymorphic HLA-restricted antigen presentation, could then trigger cross-reactive autoimmune responses. We now hope to investigate these possibilities further, with a particular focus on the roles of both antigen-presenting B cells as well as antigen-specific T cells in provoking inflammatory immune responses. In this respect, we would anticipate that targeted T-cell immunotherapy is likely to require a patient-specific approach as recently performed by Pender and colleagues \[[@pone.0147567.ref037]\], while targeting EBV-infected B cells may have the potential to provide a more universal treatment strategy, particularly in light of recent evidence that antigen-experienced B cells within the central nervous system in MS cases are likely to be derived from the peripheral blood and lymph nodes \[[@pone.0147567.ref074],[@pone.0147567.ref075]\].
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